Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer

NCT02632448 is registered in ClinicalTrials.gov with Esperas Pharma Inc. as lead sponsor.

NCT NCT02632448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02632448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Lead sponsor
Esperas Pharma Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 16, 2016
Completion date
April 14, 2025
Enrollment
229 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colon cancer, colorectal cancer, endometrial cancer, neoplasms, ovarian cancer, pancreas cancer, pancreatic cancer, rectal cancer, soft tissue sarcoma, solid tumors, triple negative breast cancer